Diagnostic Center | September 01, 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The brand is now available pan-India through their distribution partner
The drug will be marketed under the brand name Molnaflu
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
Subscribe To Our Newsletter & Stay Updated
